Abstract
Herpes Simplex Virus type 1 (HSV-1) antibodies are found in up to 90 percent of the general population. About 30% of patients who have been exposed to HSV-1 develop recurrent infections, and this degree is continually increasing. In addition, resistance to all major anti-herpetic drugs such as acyclovir (ACV) has been increasingly reported. These observations underscore the importance of discovering new therapeutic tools for the treatment of HSV-1 infections. Bifidobacterium spp. has been studied in various fields including antibacterial and anticancer effect, but the antiviral activity was studied very little. The aim of this study was to test the antiviral activity of Bifidobacterium spp. against HSV-1. The Bifidobacterium adolescentis SPM 0214 used in this study through the screening of 23 Bifidobacterium spp. by plaque assay was assessed the cell viability assay in Vero cells. We also measured the plaque reduction assay and yield reduction assay after B. adolescentis SPM 0214 treatment at concentrations ranging between 10 and 104 μg/mL. The B. adolescentis SPM 0214 was not toxic to Vero cells, and the inhibition of plaque and yield formation was obviously increased compared to those of the control (no additive). Therefore, these results indicate that antiviral activity of B. adolescentis SPM 0214 against HSV-1.
Similar content being viewed by others
References
Ahn, J. B., Isolation and characterization of Bifidobcterium Producing exopolysaccharide. Food Eng. Prog., 9, 291–296 (2005).
Bae, H. S., Shin, M. S., Kim, Y. J., and Back, Y. J., Effects of the lactic acid bacteria administration on fecal microflora and putrefactive metabolites in health adults. J. Appl. Microbiol. Biotechnol., 24, 254–260 (1996).
Benedetti, J. K., Zeh, J., and Corey, L., Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann. Intern. Med., 131, 14–20 (1999).
Boehmer, P. E. and Lehman, I. R., Herpes simplex virus DNA relplication. Annu. Rev. Biochem., 66, 347–384 (1997).
Bryson, Y., Dillon, M., and Lovett, M., Treatment of first episode genital HSV with oral acyclovir: long term followup of recurrences: a preliminary report. Scand. J. Infect. Dis., 47, 70–75 (1985).
Chatis, P. A., Miller, C. H., Shrager, L. E., and Crumparker, C. S., Successful treatment with foscarnet of an acyclovir resistant mucocutaneus infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N. Engl. J. Med., 320, 297–300 (1989).
Coen, D. M. and Schaffner, P. A., Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type. Proc. Natl. Acad. Sci. U. S. A., 77, 2265–2269 (1980).
Cross, M. L., Immunoregulation by probiotic lactobacilli: pro-Thl signals and their relevance to human health. Clin. Appl. Immunol. Rev., 3, 115–125 (2002).
De Logu, A., Williamson, R. A., Rozenshteyn Rm Ramirolbanez, F., Simpson, C. D., Burton, D. R., and Sanna, P. P., Characterization of a type-common human recombinant monoclonal to herpes simplex virus with high therapeutic potential. J. Clin. Microbiol., 36, 3198–3204 (1998).
Donohue, D. C. and Salminen, S., Safety of probiotic bacteria. Asia Pac. J. Clin. Nutr., 5, 25–28 (1996).
Donohue, D. C., Salminen, S., and Marteau, P., Safety of probiotic bacteria. In Salminen, S. and von Wright, A. (Eds.). Lactic Acid Bacteria: Microbiology and Functional Aspects. Marcel Dekker, New York, pp. 369–386, (1998).
Edwin, G., Barry, M., Tom, M., Jianhua, C., George, H., John, R., and Stephen, S., Evaluation of dendrimer SPL7013, a lead micobicide candidate against herpes simplex viruses. Antiviral. Res., 68, 139–146 (2005).
FAO/WHO, Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf (2002).
Gibbs, J. S., Chiou, H. C., Bastow, K. F., Cheng, Y. C., and Coen, D. M., Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc. Natl. Acad. Sci., U. S. A., 85, 6672–6676 (1988).
Gismongo, M. R., Drago, L., and Lombardi, A., Review of probiotics available to modify gastrointestinal flora. Int. J. Antimicrob. Agents, 12, 287–292 (1999).
Hwang, C. B., Ruffner, K. L., and Coen, D. M., A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J. Virol., 66, 1774–1776 (1992).
Kaila, M., Isolauri, E., Soppi, E., Virtanen, E., Laine, S., and Arvilommi, H., Enhancement of circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatric. Res., 32, 141–144 (1992).
Kaila, M., Isolauri, E., Saxelin, M., Arvilommi, H., and Vsikari, T., Viable versus inactivated Lactobacillus strain GG in acute rotavirus diarrhea. Arch. Dis. Child., 72, 51–53 (1995).
Kidd, P., Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev., 8, 223–246 (2003).
Lee, W. K., Lee, S. M., Bae, S. H., and Baek, Y. J., Effect of Bifidobacterium longum HY8001 administration on human fecal bacterial enzymes and microflora. J. Appl. Microbiol. Biotechnol., 24, 267–272 (1999).
Lyu, S. Y., Rhim, J. Y., and Park, W. B., Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res., 28, 1293–1301 (2005).
Marteau, P. and Salminen, S., Demonstration of safety of probiotics. Demonstraion of nutritional functionality of probiotics foods. Newsletter, 2, 3–8 (1997).
Mombelli, B. and Gismondo, M. R., The use of probiotics in medical practice. Int. J. Antimicrob. Agents, 16, 531–536 (2000).
Nugier, F., Colin, J. N., Ayamard, M., and Langlois, M., Occurrence and characterization of acyclovir-resistance herpes simplex isolates:report on a two-year sensitivity screening survey. J. Med. Virol., 36, 1–12 (1992).
Padgett, D. A., Sheridan, J. F., Dorne, J., Berntson, G. G., Candelora, J., and Glaser, R., Social stress and the reactivation of latent herpes simplex virus type 1. Proc. Natl. Acad. Sci. U. S. A., 95, 7231–7235 (1998).
Parente, E. and Ricciardi, A., Production, recovery and purification of bacteriocins from lactic acid bacteria. J. Appl. Microbiol. Biotechnol., 52, 628–638 (1999).
Penner, R., Fedorak, R. N., and Madsen, K. L., Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr. Opin. Pharmacol., 5, 596–603 (2005).
Prichard, M. N., Turk, S. R., Coleman, L. A., Engelhardt, S. L., Shipman, C., Jr., and Drach, J. C., A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods., 28, 101–106 (1990).
Raguin, G. and Malkin, J. E., Genital herpes:epidemiology and pathophysiology. Update and new perspectives. Ann. Med. Interne. (Paris), 148, 530–533 (1997).
Saddi, M., Sanna, A., Cottiglia, F., Chisu, L., Casu, L., Bonsignore, L., and De Logu, A., Antiherpevirus activity of Artemisia arborescens essential oil and inhibition of lateral diffusion in Vero cells. Ann. Clin. Microbiol. Antimicrob., 6, 10 (2007).
Safrin, S., Kemmerly, S., Plotkin, B., Smith, T., Weissbach, N., De Veranez, D., Phan, L. D., and Cohn, D., Foscarnetresistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis., 169, 193–196 (1994).
Salminen, S., Bouley, C., Boutron-Ruault, M. C., Cummings, J. H., Franck, A., Gibson, G. R., Isolauri, E., Moreau, M. C., Roberfroid, M. B., and Rowland, I., Gastrointestinal physiology and function. Br. J. Nutr., 80(Suppl), 147–171 (1998).
Salminen, S. J. and Donohue, D. C., Safety assessment of lactobalillus strain GG(ATCC53103). Nutr. Today, 31Suppl 1, 12s–15s (1996).
Sanna, P. P., De Logu, A., Williamson, R. A., Hom, Y. L., Straus, S. E., Bloom, F. E., and Burton, D. R., Protection of nude mice by passive immunization with a type common human recombinant monoclonal antibody against HSV. Virology, 215, 101–106 (1996).
Scardovi, V., Genus Bifidobacterium Orla-Jensen 1924 472AL. In Sneath, P. H. A., Mair, N. S., Sharpe, M. E., and Holt, J. G. (Eds.). Bergey’s Manual of Systemic Bacteriology. Williams & Willikins, Baltimore, pp. 1418–1434, (1986).
Siegel, M. A., Diagnosis and management of recurrent herpes simplex infections. J. Am. Dent. Assoc., 133, 1245–1249 (2002).
Silva, M., Jacobus, N. V., Deneke, C., and Gorbach, S. L., Antimicrobial substance from a human Lactobacillus strain. Antimicrob. Agents Chemother., 31, 1231–1233 (1987).
Straus, S. E., Seidlin, M., Takiff, H. E., Bachrach, S., Di-Giovanna, J. J., Western, K. A., Creagh-Kirk, T., Lininger, L., and Alling, D. W., Suppression of recurrent genital herpes with oral acyclovir. Trans. Assoc. Am. Physicians., 96, 278–283 (1983).
Tahara, T. and Kanatani, K., Isolation and partial characterization of cripacin A, a cell-associated bacteriocin produced by Bactibacillus cripatus JCM 2009. FEMS Microbiol. Lett., 147, 287–290 (1997).
Tahri, K., Grill, J. P., and Schneider, F., Involvement of trihydroxy-conjugated bile salts in cholesterol assimilation by Bifidobactera. Curr. Microbiol., 34, 79–84 (1997).
You, H. J., Oh, D. K., and Ji, G. E., Anticancerogenic effect of a novel chiroinositol-containing polysaccharide from Bifidobacterium bifidum BGN4. FEMS Microbiol. Lett., 240, 131–136 (2004).
Whitley, R. J., Herpes simplex viruses. In Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Monath, T. P., Melnick, J. L., Roizman, B., and Straus, S. E. (Eds.). Fields Virology. Lippincott Williams and Wilkins, New York, pp. 2297–2341, (1996).
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s12272-014-0514-2.
Rights and permissions
About this article
Cite this article
An, H.M., Lee, D.K., Kim, J.R. et al. Antiviral activity of Bifidobacterium adolescentis SPM 0214 against herpes simplex virus type 1. Arch. Pharm. Res. 35, 1665–1671 (2012). https://doi.org/10.1007/s12272-012-0918-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0918-9